{
    "symbol": "AGEN",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-10 15:44:11",
    "content": " So what I would say as Garo has said, we are laser-focused on our botensilimab program because the Phase 1, which is now an extended Phase 1 program is showing really remarkable activity in a number of solid tumors, and the data continues to be encouraging. For example, the expenses associated with 1571 through Phase 1 clinical trials is, relatively modest and compounds such as our CD137 are also advancing rapidly with the potential of the option holder exercising the option, which will -- when it happens, which will bring in significant additional cash resources into the company."
}